1. 29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. (September 2015) Authors: Siena, S.; Drilon, A.E.; Sai-Hong Ou, I.; Farago, A.F.; Patel, M.; Bauer, T.M.; Hong, D.; Liu, S.V.; Lee, J.; Patel, R.; Schechet, L.; Luo, D.; Chow Maneval, E.; Multani, P.S.; De Braud, F.G. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S724 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗